After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
